Kadcyla 100 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FFBS9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,195
Award facts
- Contract value 100% obligated
- $30,195.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $30,195.48 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 100 mg vials of Kadcyla, a targeted cancer therapy used in oncology treatment. Awarded on December 26, 2025, with an ultimate completion date of January 20, 2026, this delivery order carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The order will be fulfilled at DMS Pharmaceutical Group's Park Ridge location and represents part of the company's ongoing pharmaceutical supply operations for the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide pharmaceutical products and medical consumables to military healthcare facilities worldwide. The parent IDC, valued at $499,999,999 and effective through December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor capable of supplying branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. The contractor's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBS9?
SPE2DR26FFBS9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 26, 2025.
How much is contract SPE2DR26FFBS9 worth?
The government has obligated $30,195 on SPE2DR26FFBS9.
Is contract SPE2DR26FFBS9 an order under another contract?
Yes. SPE2DR26FFBS9 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBS9 competed?
The extent of competition for SPE2DR26FFBS9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award